Mode
Text Size
Log in / Sign up
Phase 4 N=22 Other

Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude

Hypertension, Pulmonary · Altitude Sickness

Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Mean Pulmonary Artery Pressure — 16.8667; 15.6545; 16.3800; 16.6833 mm Hg

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Riociguat (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Richard Moon
Primary completion
Dec 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Pulmonary Artery Pressure
16.8667; 15.6545; 16.3800; 16.6833; 15.4900; 17.4000
SECONDARY
Mean Radial Arterial Pressure
87.8333; 93.3182; 96.5600; 91.6000; 91.8000; 96.7600
SECONDARY
Mean Arterial Oxygen Saturation (SaO2)
78.3333; 84.9364; 85.4400; 81.9667; 84.4000; 83.9000
SECONDARY
Mean Ventilation Rate
14.7634; 16.8981; 18.2266; 17.5454; 18.9289; 16.4128
SECONDARY
Mean Work Rate at Exhaustion
0; 0; 0; 0; 0; 0
SECONDARY
Cardiac Output
8.11903; 6.60219; 7.53400; 8.07571; 8.98119; 7.07000

Summary

During ascent to high altitude there is a physiologic response to hypoxia that results in an elevated pulmonary arterial pressure associated with decreased exercise performance, altitude-induced pulmonary hypertension, and high altitude pulmonary edema (HAPE). Riociguat is a novel agent from Bayer Pharmaceuticals that has already demonstrated effectiveness in the treatment of pulmonary hypertension, and it may prove to be beneficial in cases of altitude-induced pulmonary hypertension or HAPE. This research study, composed of 20 healthy volunteers ages 18-40 years, will attempt to mimic the decreased oxygen supply and elevated pulmonary artery pressures found in conditions of high altitude, allowing observation of the effects of riociguat and exercise on pulmonary arterial pressure, arterial oxygenation, and exercise performance. Prior to entering the hypobaric chamber, subjects will have radial arterial lines and pulmonary artery catheters placed to obtain arterial and pulmonary artery pressure measurements. Subjects will then enter the hypobaric chamber and perform exercise tolerance tests at a simulated altitude of 15,000 feet on an electrically braked ergometer (exercise bike) before and after administration of riociguat. If, after administration of riociguat and exposure to a simulated altitude of 15,000 feet, the exercise performance is improved and observed pulmonary artery pressures are lower than those measurements seen prior to administration of riociguat, this could lead to development of a prophylactic and/or treatment strategy for HAPE and high-altitude pulmonary hypertension. Statistical analysis will compare the variables of pulmonary artery pressure, radial arterial pressure, ventilation rate, cardiac output, PaO2, and work rate at exhaustion before and after administration of the drug riociguat. The investigator's hypothesis is that riociguat will decrease pulmonary artery pressure and improve gas exchange and exercise performance at altitude.

Eligibility Criteria

Inclusion Criteria

  • Healthy males and females
  • Non-smoking
  • Non-pregnant females
  • Ages 18 - 40 years old

Exclusion Criteria

  • Serious pulmonary or cardiovascular comorbidities
  • Pregnant women
  • VO2max < 35 mL/kg per minute
  • Sickle cell trait or disease
  • Smokers
  • Lung disease
  • Hypertension
  • Cardiac disease and left bundle branch block
  • Taking nitrates, nitric oxide donors (such as amyl nitrite), and phosphodiesterase (PDE) inhibitors (including specific PDE-5 inhibitors, such as sildenafil, tadalafil, or vardenafil, or non-specific PDE inhibitors, such as dipyridamole or theophylline).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02024386). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search